Abstract
To review the pharmacological characteristics, clinical evidence, and place in therapy of voxelotor for the treatment of sickle cell disease (SCD). A comprehensive literature search of PubMed (1966 to April 2020) was conducted. Key search terms included GBT440, sickle cell, and voxelotor. Other sources were derived from bibliographies of articles, product labeling, manufacturer's website, and news releases. ClinicalTrials.gov was searched for additional studies. All English-language articles identified from the data sources were reviewed and evaluated. Case reports/series and phase 1 through 3 clinical trials were included. SCD is an inherited disorder associated with significant morbidity and early mortality. Three medications approved for SCD reduce SCD-associated complications but do not selectively ameliorate the underlying disease. Voxelotor is a novel agent that targets the pathophysiology of SCD. A phase 3 trial reported an increase in mean Hb level from baseline for voxelotor compared with placebo (1.1 vs -0.1 g/dL; P < 0.001). Voxelotor is generally well tolerated, with common adverse effects including headache, diarrhea, nausea, and arthralgia. Voxelotor may be considered for patients with SCD who have continued anemi...Continue Reading
References
Dec 12, 1982·Drug Information Journal·F B Winer
May 8, 2008·PloS One·James G TaylorMartin H Steinberg
Apr 2, 2010·American Journal of Preventive Medicine·Kathryn L Hassell
Oct 25, 2011·British Journal of Haematology·Duyen A NgoDavid H K Chui
Jul 23, 2013·PLoS Medicine·Frédéric B PielThomas N Williams
Jul 6, 2016·British Journal of Haematology·Donna OksenbergDavid R Archer
Feb 6, 2017·Lancet·Russell E WareMiguel R Abboud
Nov 19, 2017·Medical Hypotheses·J L Boucher
Mar 31, 2018·Clinica Chimica Acta; International Journal of Clinical Chemistry·Nicola J RutherfordJennifer M Colby
Apr 18, 2018·Clinical Hemorheology and Microcirculation·Kobina DufuPedro Cabrales
May 13, 2018·American Journal of Hematology·Gershwin BlydenLanetta Bronte
Jul 27, 2018·Hematology Reports·Paul TelferJosh Lehrer-Graiwer
Oct 8, 2018·Annales de cardiologie et d'angéiologie·G PouzetP Usseglio
Dec 29, 2018·American Journal of Hematology·Arun S ShetSwee Lay Thein
Jan 19, 2019·Blood·Jo HowardJoshua Lehrer-Graiwer
Feb 12, 2019·British Journal of Clinical Pharmacology·Athiwat HutchaleelahaJosh Lehrer-Graiwer
Jun 15, 2019·The New England Journal of Medicine·Elliott VichinskyUNKNOWN HOPE Trial Investigators
Nov 16, 2019·JAMA Network Open·Deborah LubeckSophie Lanzkron